Dr. O'Shaughnessy on the Future of TNBC Treatment

Joyce A. OShaughnessy, MD
Published: Thursday, Sep 15, 2011

Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, discusses the future of triple-negative breast cancer (TNBC) treatments.

O'Shaughnessy believes that TNBC is the biggest challenge currently facing breast cancer treatment. There is currently a large amount of testable hypotheses that may result in a major break-through. These hypotheses will further be strengthened by the results of the The Cancer Genome Atlas (TCGA) project for breast cancer.

The TCGA results should be submitted by the end of this year. A full sequence analysis of breast cancer will not only illuminate TNBC but also will shed light on potential subtypes of TNBC.

SELECTED
LANGUAGE
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, discusses the future of triple-negative breast cancer (TNBC) treatments.

O'Shaughnessy believes that TNBC is the biggest challenge currently facing breast cancer treatment. There is currently a large amount of testable hypotheses that may result in a major break-through. These hypotheses will further be strengthened by the results of the The Cancer Genome Atlas (TCGA) project for breast cancer.

The TCGA results should be submitted by the end of this year. A full sequence analysis of breast cancer will not only illuminate TNBC but also will shed light on potential subtypes of TNBC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x